Biography

Medical oncologist;
Head of the Gynecological and Genitourinary Cancer and Melanoma Unit.
Director of the Rare Tumors Programmes
Centro Integral Oncologico Clara Campal
Madrid

Biosketch: Jesús García-Donas

Jesus Garcia-Donas was born in Alcalá de Guadaira (Sevilla) in 1974. He received his MD from the Universidad Complutense de Madrid in 1998 and subsequently trained as Medical Oncologist at the Hospital Universitario Clinico San Carlos, Madrid. After completing his oncology training in 2002, Jesus worked first in the Hospital Universitario de Elche. In 2003 later Jesus joined the Oncology Department of the Hospital Universitario Fundación Alcorcon, focusing in hereditary cancer syndroms and genitourinary tumors. In 2009, He completed his sub-specialization in Genitourinary Tumours with a Astra-Zeneca fellowship at the New York Langone Medical Center under the supervision of Dr. Ana Ferrari. Since May 2012 Jesus leads the Genitourinary Tumors and Rare Cancer Programme at the Centro Integral Oncológico Clara Campal (Madrid).

Jesus has participated as co-investigator in up to 130 Phase I, II and III clinical trials and has published over 20 papers in peer-reviewed journals, including the prestigious The Lancet Oncology and Journal of Clinical Oncology.

Jesus currently leads several translational projects and clinical trials in the field of Kidney Cancer and Rare Tumors. Most relevant are the EuroTarget study funded by the 7th Framework Program of the European Union, that will deeply improve our knowledge of predictive biomarkers in renal tumors, the CIRClEs study (Circulating Endothelial Cells in renal cancer) and the phase II study of dovitnib, a new tyrosin kinase inhibitor, in adrenocortical carcinomas.

He has also designed and currently leads the Genedrivity (GENEtically DRIVen TrYal) Project, a pan-European study that accounts with the commitment of 8 different national collaborative groups. This study will prospectively evaluate for first time the influence of the genetic background of patients in response to targeted therapies in kidney cáncer.

Jesus has also received several grants and awards including the 2006 FREMAP award for investigational projects, the “Fundación Renal Iñigo Alvarez de Toledo” award and a grant for Independent Clinical Investigation from the Health Spanish Ministry (EC11-178).